[ad_1]
Doctors and high-risk patients are likely to receive Oxford’s Covid-19 vaccine before the end of the year. This also benefits the Norwegians.
This is the opinion of Adrian Hill, the professor leading the project for the development of a coronary vaccine at the University of Oxford, writes the Daily Mail.
He believes that we will obtain emergency approval for use of the vaccine by those who need it most, before final attempts are made. Full approval of the vaccine will come eventually, and the rest of the population will be able to receive the vaccine starting in early 2021.
Also read: Christmas Wreath: you can be denied a flight home for Christmas
According to the Daily Mail, the professor assures that billions of doses are already being produced in ten factories around the world, led by the British pharmaceutical AstraZeneca.
– I would be very surprised if the pandemic is not very clear in its descent in late spring, at least in this country. We will get to the stage where there is herd immunity through vaccination, Hill said.
Also read: Nils Atle demands a coronation test of foreign workers: the state strikes back
Two phases of successful clinical trials believe that the Oxford vaccine is safe and triggers a strong immune response. The third phase of studies is at a more advanced level.
– They will look further at the data on safety and perhaps efficacy before licensing everyone. In this country, our priorities are pretty clear … we need to vaccinate high-risk people before vaccinating young, healthy, and at-risk people, Hill said.
The Oxford vaccine may also benefit the Norwegian people. In addition to Pfizer’s coronary vaccine, the pharmaceutical company AstraZeneca and the University of Oxford are expected to have a vaccine ready soon. It is this vaccine that Norway and the EU hope will be the first to come out, with the first deliveries already in December, Nettavisen recently wrote.
Also read: Now there is talk of a second-generation coronary vaccine, what does it mean?
The vaccine, called COVID-19 Vaccine AstraZeneca, works by preparing the body to defend itself against infection by the SARS-CoV-2 coronavirus, according to the Norwegian Agency for Medicines.
[ad_2]
